Jeffrey Buchalter, a pharma industry veteran, has joined the board of Symphogen A/S as a non-executive director. Symphogen is developing recombinant antibody mixtures for cancer. Mr Buchalter has worked in both industry and the public sector including chairing the board of the US National Childhood Cancer Foundation.
Also joining the board is Christoffer Søderberg, director of large investments at Novo A/S and a former senior principal at the Boston Consulting Group. Mr Søderberg holds an MSc in finance and accounting from the Copenhagen Business School.
Symphogen announced the appointments on 11 May 2016.
Copyright 2016 Evernow Publishing Ltd